U.S. Healthtech Stock News

Dianthus Therapeutics (DNTH) has been drawing fresh attention after its recent share price moves, prompting investors to weigh how its clinical stage autoimmune drug pipeline lines up with current revenue, losses, and recent return patterns. See our latest analysis for Dianthus Therapeutics. The recent pullback, with a 30 day share price return of a 12.37% decline and a year to date share price return of a 3.75% decline at a latest share price of $38.19, contrasts with a 1 year total...

If you are wondering whether Delta Air Lines represents good value at its current price, or if the easy gains are already behind it, this article walks you through what the numbers suggest. The stock most recently closed at US$72.31, with returns of 4.7% over the past week, 3.4% over the last month, 4.7% year to date, 9.3% over one year, 94.6% over three years and 85.9% over five years. Recent attention on the stock has centered on how investors are reassessing large US carriers and the...

Recent commentary has put Patria Investments (PAX) in focus as a growth stock, pointing to its favorable Zacks Rank, expected EPS expansion and positive earnings estimate revisions as key drivers of current investor attention. See our latest analysis for Patria Investments. Patria’s US$17.28 share price sits against a recent pattern where the 90 day share price return of 25.22% and 1 year total shareholder return of 60.40% point to momentum building around the growth story highlighted by...

In recent months, Gorman-Rupp reported record quarterly results that exceeded analyst expectations, supported by strong infrastructure-related sales and a double-digit increase in incoming orders. At the same time, renewed interest from institutional investors and a rotation toward industrial and defensive names in light of higher proposed government infrastructure and defense spending have sharpened attention on Gorman-Rupp’s order momentum and end-market exposure. We’ll now look at how...

If you are wondering whether BridgeBio Pharma's share price still reflects its underlying value after a strong run, you are not alone. The stock recently closed at US$77.25, with returns of 6.3% over the last 30 days, a 1.3% decline over the past week, and about 166% over the past year, while the 3 year return figure is very large. Recent news around BridgeBio Pharma has focused on its clinical stage pipeline, partnership activity and regulatory milestones. These factors can all influence...

CG Oncology (CGON) has drawn attention after recent share price moves, with the stock last closing at US$54.20. Investors are weighing that level against the company’s current fundamentals and recent clinical progress. See our latest analysis for CG Oncology. The latest move sits on top of strong recent momentum, with a 1 day share price return of 29.26%, a 30 day share price return of 29.85% and a 1 year total shareholder return of 79.47%. Together, these figures suggest that investors are...

Roku (ROKU) has drawn investor attention after recent share price moves, with the stock up 2.1% over the past week and 5.5% over the past month, prompting closer scrutiny of its current valuation. See our latest analysis for Roku. While the share price is now at $111.17, the recent 30-day share price return of 5.51% sits alongside a 90-day share price return of 20.81% and a 1-year total shareholder return of 40.38%, suggesting momentum has been building over the medium term even as longer...

BioStem Technologies: Recent Moves and Context for Investors BioStem Technologies (BSEM) has drawn fresh investor attention after recent trading, with the stock closing at $5.00 and showing mixed performance across the past week, month, and past 3 months. See our latest analysis for BioStem Technologies. That sharp 17.65% 1 day share price return, on top of a 27.91% year to date share price return, contrasts with a 1 year total shareholder return of a 66.67% decline. As a result, recent...

If you are wondering whether Albemarle's share price still reflects its true worth, you are not alone. Many investors are asking if the current price lines up with the fundamentals. The stock last closed at US$161.29, with recent returns of 12.1% over 7 days, 21.1% over 30 days, 12.1% year to date and 90.3% over the past year, while the 3 year and 5 year returns stand at 30.4% and 5.0% declines respectively. Recent coverage around Albemarle has focused on its role as a major lithium producer...

Gates Industrial (GTES) moved higher after investors reacted to President Trump’s proposed US$1.5 trillion defense budget for 2027 and steadier energy costs, which together lifted interest in industrial and engineered components names. See our latest analysis for Gates Industrial. That move sits within a mixed year for the stock, with a 1-day share price return of 1.33% and 7-day gain of 3.31% set against a 90-day share price return of 6.79% decline. The 1-year total shareholder return of...

On January 5, 2026, Corebridge Financial announced it had completed major reinsurance transactions covering its individual retirement variable annuities and sold SunAmerica Asset Management to Venerable Holdings, aligning more tightly around core retirement solutions. This reshaping of its business mix, combined with recent S&P MidCap 400 inclusion and preferred stock issuance, marks a meaningful shift in how Corebridge manages risk, capital, and long-term focus. We’ll now examine how the...

If you are wondering whether United Natural Foods at around US$32.52 offers good value today, it helps to first separate short term price noise from the underlying business and what you are actually paying for it. The stock has been fairly flat over the last month with a 0.0% 30 day return, yet it is up 19.2% over the past year and still shows a 20.9% decline over three years alongside a 46.5% gain over five years, which can leave investors unsure how to read the risk and reward trade...

Abercrombie & Fitch has recently reignited its brand buzz by reviving its Millennial-favorite Fierce fragrance, launching new campaigns, and running broad winter promotions, all while continuing to post earnings and revenue results that have exceeded market expectations. At the same time, growing analyst optimism and bullish options activity suggest that this brand and sales momentum is reshaping how investors think about Abercrombie & Fitch’s business prospects. We’ll now explore how this...

If you are wondering whether Globant's current share price reflects its true worth, you are not alone. This article is here to unpack that question in a clear, practical way. The stock last closed at US$68.39, with returns of 8.4% over the past week, a 0.8% decline over 30 days, 8.4% year to date, and declines of 67.0% over 1 year, 59.4% over 3 years, and 67.2% over 5 years. These moves have put Globant back on many investors' watchlists, as the sharp multi year pullback sits alongside a...

Wondering if Jazz Pharmaceuticals is still offering value at around US$161 a share, or if most of the opportunity has already been priced in? The stock is up 32.7% over the past year, even though it has seen a 6.9% decline over the last week and a 2.3% decline over the past month. Recent attention on Jazz Pharmaceuticals has centered on its position in pharmaceuticals and biotech, with investors weighing the company against sector peers and sentiment around the broader drug development...

Scholar Rock Holding (SRRK) has drawn investor attention after recent share price moves, with the stock last closing at US$42.18. That price sits against a mixed return profile across the past month and the past 3 months. See our latest analysis for Scholar Rock Holding. Looking past the recent pullback, Scholar Rock Holding’s 30 day share price return of a 6.37% decline contrasts with a 6.89% gain over 90 days. The 3 year total shareholder return of about 3.5x suggests momentum has broadly...

If you are wondering whether Pure Storage is still reasonably priced after its long run as a data storage name, it helps to step back and look at how the current share price lines up with its fundamentals. The stock last closed at US$66.98, with returns of 3.5% over the past year, a 153.1% gain over 3 years and 193.0% over 5 years. The more recent 7 day and 30 day moves of 2.9% and 9.1% declines hint at shifting expectations and risk perceptions in the short term. Recent attention on Pure...

PROCEPT BioRobotics (PRCT) is back in focus after a flurry of analyst updates, including a downgrade from Bank of America that sits alongside more optimistic views on future utilization and long-term market potential. See our latest analysis for PROCEPT BioRobotics. The recent analyst flurry comes after a choppy stretch for PROCEPT BioRobotics, with a 7 day share price return of 6.73% following a 1 day decline of 4.79% and a 1 year total shareholder return of 62.20% in the red. This suggests...

Nasdaq, Inc. recently reported its December 2025 trading volumes and Q4 operational metrics, while also setting January 29, 2026, for its fourth-quarter and full-year 2025 earnings release and investor conference call, which will feature senior management commentary and Q&A. These disclosures, alongside increased equity trading activity and expanding technology offerings such as Verafin and broader fintech solutions, have intensified attention on how Nasdaq’s business mix and transaction...

If you are wondering whether Under Armour at around US$5.64 is a bargain or a value trap, you are not alone. The answer depends heavily on how you look at its valuation. The stock has recently shown sharp moves, with a 6.6% return over the last week and 28.8% over the last 30 days, against a 6.6% return year to date and longer term returns of a 31.3% decline over 1 year, a 50.9% decline over 3 years, and a 68.8% decline over 5 years. Recent headlines have focused on Under Armour's brand...

Iovance Biotherapeutics (IOVA) recently told investors it expects to meet its 2025 revenue guidance of US$250 million to US$300 million, while surpassing 1,000 patients treated with its tumor infiltrating lymphocyte therapies globally. See our latest analysis for Iovance Biotherapeutics. The revenue guidance update and patient milestone come after a mixed stretch for investors, with the share price at US$2.45 and a 1-month share price return of 8.89% and a 90-day share price return of 16.67%,...

If you are wondering whether Tesla's share price still makes sense for you at today's levels, the key question is what you are really paying for when you buy the stock. Tesla last closed at US$445.01, with returns of 1.6% over the past week, a 0.4% decline over the past month, 1.6% year to date and 12.7% over the last year, while the 3 year and 5 year returns sit at 263.6% and 61.6% respectively. Recent headlines around Tesla have continued to focus on its role as a major electric vehicle...

Lamb Weston Holdings has already moved to close its Munro, Argentina plant and consolidate Latin American production at its newer Mar del Plata facility, while temporarily curtailing a production line in the Netherlands as part of its Focus to Win cost-efficiency program. This reshaping of its international manufacturing footprint highlights how the company is leaning on plant consolidation and capacity adjustments to pursue margin and efficiency gains across its global network. We’ll now...

Ameris Bancorp (ABCB) is back on investors’ radar after recent trading, with the stock last closing at $79.13 and showing positive total returns over the past year, past 3 months, and month. See our latest analysis for Ameris Bancorp. The recent share price move to $79.13 comes on top of a 6.96% 7 day share price return and a 34.75% 1 year total shareholder return, which suggests momentum is building rather than fading. If Ameris Bancorp has caught your attention, it could be a good moment to...